RNAC

Cartesian Therapeutics, Inc. Common Stock

6.89

USD

-0.13

-1.85%

Nov 10, 15:59 UTC -5

Closed

After-Market

6.88

0.00

-0.07%

Cartesian Therapeutics, Inc. Common Stock (RNAC) Earnings

RNAC Earnings Reports

Positive Surprise Ratio

RNAC beat 20 of 42 last estimates.

48%

Next Report

Date of Next Report

Mar 08, 2027

Estimate for Q4 26 (Revenue/ EPS)

$348.50K

-$0.94

Implied change from Q3 26 (Revenue/ EPS)

+147.37%

Implied change from Q4 25 (Revenue/ EPS)

-63.20%

-73.67%

Cartesian Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 05, 2026, RNAC reported earnings of -0.38 USD per share (EPS) for Q3 26, beating the estimate of -0.95 USD, resulting in a 60.38% surprise. Revenue reached --, compared to an expected 116.58 thousand, with a -100.00% difference. The market reacted with a -0.59% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.94 USD, with revenue projected to reach 348.50 thousand USD, implying an increase of 147.37% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Cartesian Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Cartesian Therapeutics, Inc. Common Stock reported EPS of -$0.38, beating estimates by 60.38%, and revenue of $0.00, -100% below expectations.

How did the market react to Cartesian Therapeutics, Inc. Common Stock's Q3 2026 earnings?

The stock price moved down -0.59%, changed from $6.82 before the earnings release to $6.78 the day after.

When is Cartesian Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 08, 2027.

What are the forecasts for Cartesian Therapeutics, Inc. Common Stock's next earnings report?

Based on -- analysts, Cartesian Therapeutics, Inc. Common Stock is expected to report EPS of -$0.94 and revenue of $348.50K for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.